Next Article in Journal
ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma
Next Article in Special Issue
Survival Impact of Chronic Obstructive Pulmonary Disease or Acute Exacerbation on Patients with Rectal Adenocarcinoma Undergoing Curative Resection: A Propensity Score-Matched, Population-Based Cohort Study
Previous Article in Journal
Fluorescence Image-Guided Surgery for Thyroid Cancer: Utility for Preventing Hypoparathyroidism
Previous Article in Special Issue
Colorectal Cancer Patients Have Four Specific Bacterial Species in Oral and Gut Microbiota in Common—A Metagenomic Comparison with Healthy Subjects

Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications

by 1,2,3, 1,2,3,4, 1,2,3,4 and 1,2,3,5,*
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France
Institut National de la Santé et de la Recherche Médicale (INSERM) U938, 75012 Paris, France
Institut Universitaire de Cancérologie (IUC), Faculté de Médecine, Sorbonne Université, 75005 Paris, France
Centre National de la Recherche Scientifique (CNRS), 75016 Paris, France
Department of Endocrinology and Oncology Biochemistry, Pitié-Salpetrière Hospital, 75013 Paris, France
Author to whom correspondence should be addressed.
Academic Editor: Leticia Moreira
Cancers 2021, 13(15), 3793;
Received: 16 June 2021 / Revised: 21 July 2021 / Accepted: 22 July 2021 / Published: 28 July 2021
(This article belongs to the Special Issue New Insights into Colorectal Cancer)
The mortality of colorectal cancer is principally related to metastatic disease at the time of diagnosis or to the growth of initially undetectable micro-metastasis. Current therapeutic strategies are efficient in patients with locally advanced cancer, but are rarely able to cure patients with metastatic disease. Therapeutic failure is mainly associated with drug resistance and an aggressive phenotype. The identification of new biomarkers for micro-metastasis and tumor progression remains an unmet clinical need that should allow for improved patient stratification for optimal treatment and may lead to the identification of novel therapeutic targets. Osteopontin (OPN), a multifunctional protein, has emerged as a potentially valuable biomarker in several cancer types. This review principally describes the molecular mechanisms of OPN that are associated with colorectal cancer (CRC) progression and metastasis, as well as the use of OPN as a clinical biomarker. This review identifies a role for OPN as a biomarker ready for extended clinical application and discusses its use as a therapeutic target.
A high expression of the phosphoprotein osteopontin (OPN) has been associated with cancer progression in several tumor types, including breast cancer, hepatocarcinoma, ovarian cancer, and colorectal cancer (CRC). Interestingly, OPN is overexpressed in CRC and is associated with a poor prognosis linked to invasion and metastasis. Here, we review the regulation and functions of OPN with an emphasis on CRC. We examine how epigenetic and genetic regulators interact with the key signaling pathways involved in this disease. Then, we describe the role of OPN in cancer progression, including proliferation, survival, migration, invasion, and angiogenesis. Furthermore, we outline the interest of using OPN as a clinical biomarker, and discuss if and how osteopontin can be implemented as a routine assay in clinical laboratories for monitoring CRC patients. Finally, we discuss the use of OPN an attractive, but challenging, therapeutic target. View Full-Text
Keywords: osteopontin; colorectal cancer (CRC); biomarker; therapeutic target; metastasis osteopontin; colorectal cancer (CRC); biomarker; therapeutic target; metastasis
Show Figures

Figure 1

MDPI and ACS Style

Amilca-Seba, K.; Sabbah, M.; Larsen, A.K.; Denis, J.A. Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers 2021, 13, 3793.

AMA Style

Amilca-Seba K, Sabbah M, Larsen AK, Denis JA. Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers. 2021; 13(15):3793.

Chicago/Turabian Style

Amilca-Seba, Katyana, Michèle Sabbah, Annette K. Larsen, and Jérôme A. Denis. 2021. "Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications" Cancers 13, no. 15: 3793.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop